Comparison of Pharmocokinetics of Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Calcineurininhibitor-free Treated Patients After Renal Transplantation

Trial Profile

Comparison of Pharmocokinetics of Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Calcineurininhibitor-free Treated Patients After Renal Transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2014

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 09 Oct 2014 The dose of mycophenolate mofetil has been changed from 500mg or 250 mg/day to 1 g/day and mycophenolate sodium from 180 or 360 mg/day to 720 mg as reported by ClinicalTrials.gov record.
    • 26 May 2010 Status changed from recruiting to completed as reported by Roche record.
    • 25 May 2010 Actual number of patients (23) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top